Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond
or become resistant to current treatment. DS-8201a is a new experimental product that is a
combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may
slow down tumor growth. This might improve outcomes for these patients.
Phase
Phase 2
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Enrollment Eligibility
Inclusion Criteria:
- Men or women the age of majority in their country
- Has pathologically documented breast cancer that:
1. is unresectable or metastatic
2. has HER2 positive expression confirmed per protocol
- Has an adequate tumor sample
- Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1
- Has protocol-defined adequate cardiac, renal and hepatic function
- Agrees to follow protocol-defined method(s) of contraception
Exclusion Criteria:
- Has a medical history of myocardial infarction, symptomatic congestive heart failure
(CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia
- Has a corrected QT interval (QTc) prolongation to > 450 millisecond (ms) in males and
> 470 ms in females
- Has a medical history of clinically significant lung disease
- Is suspected to have certain other protocol-defined diseases based on imaging at
screening period
- Has history of any disease, metastatic condition, drug/medication use or other
condition that might, per protocol or in the opinion of the investigator, compromise:
1. safety or well-being of the participant or offspring
2. safety of study staff
3. analysis of results